AGN 195183是一种具有口服活性的维甲酸受体α（RARα）选择性激动剂。
Cas No.:367273-07-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
AGN 195183 is an orally active, selective agonist for the retinoic acid receptor α (RARα)[1-2]. AGN 195183 has high affinity for RARα (Kd=3nM) and is inactive against RARβ/γ. AGN 195183 is used in research related to acute myeloid leukemia, multiple myeloma, and breast cancer[3].
In vitro, AGN 195183 (0-1μM) was used to treat the ER-positive human breast cancer cell line T-47D and the ER-negative human breast cancer cell line SK-BR-3 for 1-8 days. AGN 195183 significantly inhibited cell growth[4]. Treatment of the human promyelocytic leukemia cell line NB-4 with AGN 195183 (100nM) for 96 hours effectively induced neutrophil differentiation; co-treatment of NB-4 cells with AGN 195183 (100nM) and 10nM 1,25-dihydroxyvitamin D3 for 96 hours effectively induced monocyte differentiation[5].
In vivo, AGN 195183 (4mg/kg/day and 20mg/kg/day) was administered orally to treat Wistar rats with glomerulonephritis (Thy-GN), starting from day 23 after model induction and continuing for 67 days. AGN 195183 significantly reduced protein excretion and blood pressure, improved histological indices such as the glomerulosclerosis index, glomerular and interstitial cell counts, and interstitial area, and reduced glomerular macrophage infiltration and the gene expression of TGF-β1 and Prepro-ET-1[6]. AGN 195183 (4, 12, 36mg/kg/day; for 20 days) was administered daily by gavage to 2-month-old female CD-1 mice subcutaneously implanted with a Matrigel/rhBMP-2 mixture. AGN 195183 significantly inhibited the formation of ectopic bone-like tissue, reduced mineralized tissue volume, cartilage and bone content, the number of TRAP-positive osteoclasts and vascularization, and downregulated the expression of key chondrogenic and osteogenic genes such as Sox9, Runx2, and VEGFα[7].
References:
[1] Wang Q, Lee D, Sysounthone V, et al. 1,25-dihydroxyvitamin D3 and retonic acid analogues induce differentiation in breast cancer cells with function- and cell-specific additive effects. Breast Cancer Res Treat. 2001 May;67(2):157-68.
[2] Chee LC, Hendy J, Purton LE, et al. ATRA and the specific RARα agonist, NRX195183, have opposing effects on the clonogenicity of pre-leukemic murine AML1-ETO bone marrow cells. Leukemia. 2013 Jun;27(6):1369-80.
[3] Herbert KE, Walkley CR, Winkler IG, et al. Granulocyte colony-stimulating factor and an RARalpha specific agonist, VTP195183, synergize to enhance the mobilization of hematopoietic progenitor cells. Transplantation. 2007 Feb 27;83(4):375-84.
[4] Beard RL, Duong TT, Teng M, et al. Synthesis and biological activity of retinoic acid receptor-alpha specific amides. Bioorg Med Chem Lett. 2002 Nov 4;12(21):3145-8.
[5] Brown G, Marchwicka A, Cunningham A, et al. Antagonizing Retinoic Acid Receptors Increases Myeloid Cell Production by Cultured Human Hematopoietic Stem Cells. Arch Immunol Ther Exp (Warsz). 2017 Feb;65(1):69-81.
[6] Schaier M, Liebler S, Schade K, et al. Retinoic acid receptor alpha and retinoid X receptor specific agonists reduce renal injury in established chronic glomerulonephritis of the rat. J Mol Med (Berl). 2004 Feb;82(2):116-25.
[7] Shimono K, Morrison TN, Tung WE, et al. Inhibition of ectopic bone formation by a selective retinoic acid receptor alpha-agonist: a new therapy for heterotopic ossification? J Orthop Res. 2010 Feb;28(2):271-7.
AGN 195183是一种具有口服活性的维甲酸受体α（RARα）选择性激动剂[1-2]。AGN 195183对RARα具有高亲和力（Kd=3nM），对RARβ/γ无活性。AGN 195183可用于急性髓性白血病、多发性骨髓瘤和乳腺癌的相关研究[3]。
在体外，AGN 195183（0-1μM）处理ER阳性人乳腺癌细胞系T-47D和ER阴性人乳腺癌细胞系SK-BR-3 1-8天。AGN 195183显著抑制细胞生长[4]。AGN 195183（100nM）处理人早幼粒细胞白血病细胞系NB-4 96小时，可有效诱导中性粒细胞分化；AGN 195183（100nM）与10nM 1,25-二羟基维生素D3联合处理NB-4细胞96小时，可有效诱导单核细胞分化[5]。
在体内，AGN 195183（4mg/kg/天及20mg/kg/天）口服处理，用于从造模后第23天开始、持续67天治疗肾小球肾炎（Thy-GN）的Wistar大鼠。AGN 195183显著降低了蛋白质排泄和血压，改善了肾小球硬化指数、肾小球及间质细胞计数、间质面积等组织学指标，并减少了肾小球巨噬细胞浸润及TGF-β1、Prepro-ET-1的基因表达[6]。AGN 195183（4、12、36mg/kg/天）通过灌胃每天给药，用于处理皮下植入Matrigel/rhBMP-2混合物的2月龄雌性CD-1小鼠，连续20天。AGN 195183显著抑制了异位骨样组织的形成，减少了矿化组织体积、软骨和骨含量、TRAP阳性破骨细胞数量及血管分布，并下调了Sox9、Runx2、VEGFα等成软骨和成骨关键基因的表达[7]。
| Cell experiment [1]: | |
Cell lines | T-47D cells (human breast cancer cell line, estrogen receptor positive) and SK-BR-3 cells (human breast cancer cell line, estrogen receptor negative) |
Preparation Method | The cell lines were maintained in Dulbecco's minimal essential medium (DMEM) supplemented with 10% fetal bovine serum (FBS). Cells were treated with the AGN 195183 (0-1μM) for 1-8 days. |
Reaction Conditions | 0-1μM; 1-8 days. |
Applications | AGN 195183 significantly inhibited the growth of T-47D cells by approximately 60% and inhibited the growth of SK-BR-3 cells by approximately 93%. |
| Animal experiment [2]: | |
Animal models | Male Wistar rats with established chronic anti-Thy1.1 glomerulonephritis (Thy-GN) |
Preparation Method | Chronic mesangioproliferative Thy-GN was induced in rats by intravenous injection of monoclonal antibody (MoAb) 1-22-3. Oral treatment with AGN 195183 (4 or 20mg/kg/day) began on day 23 after disease induction and continued for 45 days. |
Dosage form | 4 or 20mg/kg/day; p.o.; daily administration for 45 days. |
Applications | AGN 195183 significantly reduced albuminuria and normalized elevated blood pressure in nephritic rats. AGN 195183 also significantly improved renal histology, as indicated by a lower glomerulosclerosis index, reduced glomerular and interstitial cell counts, and a smaller interstitial area. AGN 195183 treatment decreased glomerular macrophage infiltration and attenuated the increased glomerular gene expression of TGF-β1 and prepro-ET-1. |
References: | |
| Cas No. | 367273-07-2 | SDF | |
| 别名 | IRX-5183; VTP-195183; NRX-195183 | ||
| Canonical SMILES | O=C(O)C1=C(F)C=C(NC(C2=C(O)C(Cl)=C3C(C)(C)CCC(C)(C)C3=C2)=O)C=C1F | ||
| 分子式 | C22H22ClF2NO4 | 分子量 | 437.86 |
| 溶解度 | DMSO: ≥ 62 mg/mL (141.60 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2838 mL | 11.4192 mL | 22.8384 mL |
| 5 mM | 456.8 μL | 2.2838 mL | 4.5677 mL |
| 10 mM | 228.4 μL | 1.1419 mL | 2.2838 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet